Program
NNC0662-0419
A development code.
Its studies are mostly in Obesity · Diabetes Mellitus, Type 2, led by Novo Nordisk.
Furthest: phase 2, since Sep 18, 20256 company-led studies, 4 open or runningNext primary completion: Dec 14, 2026 (phase 2)
Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Novo Nordisk | 64 open or running | phase 2since Sep 18, 2025 | Dec 12, 2024 | Dec 14, 2026phase 2 · NCT07184632 |
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
- Dec 12, 2024First study: phase 1 study in OverweightFirst studyNCT06737536 · 100 enrolled · United States
- Jul 28, 2025Phase 1 study in OverweightNCT07101783 · 100 enrolled · United States
- Sep 18, 2025Phase 2 study in OverweightNCT07184632 · 224 enrolled · United States
- Feb 11, 2026Phase 2 study in Diabetes Mellitus, Type 2NCT07415954 · 270 planned · United States, Croatia, Hungary and more
- Apr 6, 2026Phase 1 study in OverweightNCT07525791 · 41 enrolled · United States
- Jun 5, 2026Phase 2 study in ObesityNCT07639021 · 233 enrolled · United States, Puerto Rico
Ahead
- Dec 14, 2026Primary completion: phase 2 study in OverweightNCT07184632
- May 2, 2027Primary completion: phase 1 study in OverweightNCT07525791
- Jun 14, 2027Primary completion: phase 2 study in ObesityNCT07639021
- Sep 3, 2027Primary completion: phase 2 study in Diabetes Mellitus, Type 2NCT07415954
TargetBeta
Not stated by its company or a source we have read. Most early programs say nothing of it.
Studies
All 6 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Primary completion | Size |
|---|---|---|---|---|
| NCT07639021Obesity · United States, Puerto Rico | 2 | Active, not recruiting | Jun 14, 2027 | 233 |
| NCT07525791Overweight · United States | 1 | Active, not recruiting | May 2, 2027 | 41 |
| NCT07415954Diabetes Mellitus, Type 2 · United States, Croatia, Hungary and more | 2 | Recruiting | Sep 3, 2027 | 270 |
| NCT07184632Overweight · United States | 2 | Active, not recruiting | Dec 14, 2026 | 224 |
| NCT07101783Overweight · United States | 1 | Completed | Oct 31, 2025 | 100 |
| NCT06737536Overweight · United States | 1 | Completed | Jul 26, 2025 | 100 |
How it is read
Names in the registry
- “NNC0662-0419”, 6 entries
Codes read as this program: NNC06620419.
Conditions, from the studies’ own filings
- Obesity, 5 studies
- Diabetes Mellitus, Type 2, 1 study
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.